NEW YORK, October 9, 2018 /PRNewswire/ --
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic
Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children.
Q BioMed continues to develop its intellectual property including its patent pending QBM-001 drug technology, which is being
tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders. Working with its medical
and scientific advisors, Q BioMed is focusing on QBM001 candidate formulations that seek to provide an improved safety profile in
preclinical studies. Q BioMed has visited with many potential trial sites in the U.S. and Europe
over the last 9 months in preparation for the planned clinical trial of its drug candidate.
Denis Corin, CEO of Q BioMed Inc. stated, "We are grateful for the feedback from clinicians,
patients and their families and medical and scientific advisors. All are excited about the roadmap for QBM-001 over the next 6
months and look forward to reporting on our progress."
QBM-001 targets toddlers with pediatric developmental nonverbal disorder, where an underlying commonality of this subgroup is
elevated blood markers that lead to developmental delay, an autism diagnosis and eventual nonverbal or very minimally verbal
capability for the rest of their lives.
Although the nonverbal or very minimally verbal subgroup is definable by the lack of language development, there is no
diagnostic tool to identify the children at risk at an early age. As such, Q BioMed has vetted diagnostic options over the last 9
months that could offer a way to diagnose these children as early as two years of age. These tools will be a part of the upcoming
clinical trial in order to help validate them as potential biomarkers. Q BioMed is looking forward to announcing these
partnerships in the coming months as we complete and submit the regulatory filings required for orphan drug designation and an
IND to initiate the planned clinical trial.
In preparation for the clinical trial, Q BioMed is preparing partnerships with a Contract and Development Manufacturing
Organization (CDMO) to start manufacturing, and Contract Research Organizations (CROs) to finish preclinical studies, submit a
pre-IND, orphan drug designation filing and continue to secure its intellectual property through patent filings.
About Pediatric Development Nonverbal Disorder
There are approximately 18,000 new cases of pediatric developmental nonverbal disorder in the US each year and a similar
amount in Europe. The majority of the children are diagnosed as young children and fall within
the autism and epilepsy spectrum disorders. Individually, the economic costs for toddlers that become non- or minimally verbal is
ten million dollars on average per person over their life. Collectively, an estimated 200 billion dollars is spent yearly on individuals who have become nonverbal in the US. Not all individuals who
become nonverbal will benefit from QBM-001. However, with validated biomarkers, testing from trained specialists and genetic
testing, children who fall in this targeted population can be identified, and will have a higher likelihood of responding to
treatment.
About Q BioMed Inc.
Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued
biomedical assets in the healthcare sector. Q is dedicated to providing these target assets, strategic resources, developmental
support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients
in need.
Please visit http://www.qbiomed.com for more information and signup for
regular updates. Also, follow us on Social Media @QbioMed #QbioMed $QBIO
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock price. Factors that could cause actual results to differ
materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research
and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and
relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability
to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any
forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435
SOURCE Q BioMed Inc.